Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Idraparinux. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 known ✓ | P00742 | 6/20 | 0.56 |
| ▸ | SERPINC1 | P01008 | 3/20 | 0.85 |
| ▸ | FGF1 | P05230 | 4/20 | 0.57 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | FGF2 | P09038 | 1/20 | 0.52 |
| ▸ | HPSE | Q9Y251 | 5/20 | 0.48 |
| ▸ | BDNF | P23560 | 2/20 | 0.41 |
| ▸ | PTN | P21246 | 1/20 | 0.41 |
| ▸ | MDK | P21741 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Idraparinux SCHEMBL427808 | 1.00 | SERPINC1 (0.85) | SERPINC1FGF1F10F2FGF2 | |
| SCHEMBL29407493 | 1.00 | SERPINC1 (0.85) | SERPINC1FGF1F10F2FGF2 | |
| SCHEMBL12458587 | 0.93 | SERPINC1 (0.75) | SERPINC1FGF1F10F2FGF2 | |
| SCHEMBL12729453 | 0.92 | SERPINC1 (0.74) | SERPINC1FGF1F10F2FGF2 | |
| SCHEMBL15896273 | 0.88 | SERPINC1 (0.69) | SERPINC1FGF1F10F2FGF2 | |
| SCHEMBL12799309 | 0.87 | SERPINC1 (0.68) | SERPINC1FGF1F10F2FGF2 | |
| SCHEMBL17660081 | 0.86 | SERPINC1 (0.66) | SERPINC1FGF1F10F2FGF2 | |
| SCHEMBL13551204 | 0.86 | SERPINC1 (0.66) | SERPINC1FGF1F10F2FGF2 | |
| SCHEMBL4732494 | 0.86 | SERPINC1 (0.66) | SERPINC1FGF1F10F2FGF2 | |
| SCHEMBL29890443 | 0.85 | SERPINC1 (0.65) | SERPINC1FGF1F10F2FGF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 962 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097063-A1 | ANTI-C5 ANTIBODY/C5 IRNA DOSING REGIMENS FOR TREATING C5-ASSOCIATED DISEASES | REGENERON PHARMA (US) | 2026-04-09 | — | — | US | claimed |
| US-20250326778-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2025-10-23 | — | — | US | claimed |
| EP-4608449-A1 | ANTI-C5 ANTIBODY/C5 IRNA CO-FORMULATIONS AND COMBINATION THERAPIES | Regeneron Pharmaceuticals, Inc. (US) | 2025-09-03 | — | — | EP | claimed |
| US-20250262284-A1 | METHODS FOR TREATING AND PREVENTING NEUTROPHIL-DERIVED NET TOXICITY AND THROMBOSIS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-08-21 | — | — | US | claimed |
| WO-2025150072-A1 | A STABLE ORAL PRO-DISPERSION FORMULATION AND IMPLEMENTATIONS THEREOF | PULSE PHARMACEUTICALS PVT LTD (IN) | 2025-07-17 | — | — | WO | claimed |
| US-20250186563-A1 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | ALEXION PHARMA INC (US) | 2025-06-12 | — | — | US | claimed |
| EP-3604510-B1 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | ALEXION PHARMA INC (US) | 2025-03-26 | — | — | EP | claimed |
| US-20250092380-A1 | ANTIDOTES TO FACTOR XA INHIBITORS | ALEXION PHARMA INC (US) | 2025-03-20 | — | — | US | claimed |
| US-20250064891-A1 | HOST PROTEASES ESSENTIAL FOR PARAINFLUENZA SPREAD IN THE HUMAN LUNG: POTENTIAL TARGETS FOR ANTIVIRAL INTERVENTIONS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2025-02-27 | — | — | US | claimed |
| US-20250034100-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS INC (US) | 2025-01-30 | — | — | US | claimed |
| US-11377428-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | claimed |
| US-11370765-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2022-06-28 | — | — | US | claimed |
| US-11370764-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS INC. (US) | 2022-06-28 | — | — | US | claimed |
| EP-4013432-A1 | THROMBOSOMES AS AN ANTICOAGULANT REVERSAL AGENT | Cellphire Inc. (US) | 2022-06-22 | — | — | EP | claimed |
| EP-4013784-A1 | HIGH CONCENTRATION ANTI-C5 FORMULATIONS | Regeneron Pharmaceuticals, Inc. (US) | 2022-06-22 | — | — | EP | claimed |
| WO-2022125878-A1 | COMPOSITIONS AND METHODS FOR PREVENTING, ATTENUATING, AND TREATING MEDICAL CONDITIONS WITH SHDL NANOPARTICLES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-06-16 | — | — | WO | claimed |
| US-11332451-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (GA) | 2022-05-17 | — | — | US | claimed |
| US-11318331-B2 | Pulmonary hypertension treatment | SONIVIE LTD. (IL) | 2022-05-03 | — | — | US | claimed |
| WO-2022087058-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR RELATED DISORDERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-04-28 | — | — | WO | claimed |
| EP-3964208-A1 | COMPOSITION COMPRISING ISOQUERCETIN FOR TREATING VENOUS THROMBOSIS | Quercegen Pharmaceuticals LLC (US) | 2022-03-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092380-A1 | ANTIDOTES TO FACTOR XA INHIBITORS | SERPINC1, F2, F8 | F10 6/4885SERPINC1 1/4885FGF1 4093/4885 |
| US-20260097063-A1 | ANTI-C5 ANTIBODY/C5 IRNA DOSING REGIMENS FOR TREATING C5-ASSOCIATED DISEASES | LDLR, CHRNG, FCGR2A | F10 866/4885SERPINC1 340/4885FGF1 4189/4885 |
| US-20250186563-A1 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | SERPINC1, F8, F9 | F10 6/4885SERPINC1 1/4885FGF1 4243/4885 |
| US-20250326778-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | IRAK3, IRAK1, IRAK2 | F10 4797/4885SERPINC1 2958/4885FGF1 4252/4885 |
| US-11377428-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | F10 4378/4885SERPINC1 2307/4885FGF1 3214/4885 |
| US-11332451-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | F10 4378/4885SERPINC1 2307/4885FGF1 3214/4885 |
| US-20250034100-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | F10 4378/4885SERPINC1 2307/4885FGF1 3214/4885 |
| US-11370764-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | F10 4378/4885SERPINC1 2307/4885FGF1 3214/4885 |
| US-20250262284-A1 | METHODS FOR TREATING AND PREVENTING NEUTROPHIL-DERIVED NET TOXICITY AND THROMBOSIS | ELANE, MPO, MMP8 | F10 197/4885SERPINC1 4/4885FGF1 3051/4885 |
| US-11370765-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | F10 4378/4885SERPINC1 2307/4885FGF1 3214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.